Study Details

Back to Search Results

A long term study of intermittent oral dosing of ASP1517 in hemodialysis chronic kidney disease patients with anemia converted from Erythropoieses Stimulating Agent (ESA) treatment

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT02779764

Astellas Study ID

The unique identification code given by the study sponsor.

1517-CL-0312

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Follow Trial

Condition

Dialysis in Kidney Disease with Anemia

Phase

These clinical trials are done to confirm that an experimental treatment helps participants who have a specific condition. These clinical trials often compare the experimental treatment to another treatment or, if appropriate, a placebo.

Phase 3

Age

20 years - N/A

Sex

Female & Male

Product

N/A

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

May 2016 - Nov 2017

Masking

None (Open Label)

Enrollment number

164

A Phase 3, Long-term study of intermittent oral dosing of ASP1517 in hemodialysis chronic kidney disease patients with anemia converted from erythropoiesis stimulating agent treatment

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A long term study of intermittent oral dosing of ASP1517 in hemodialysis chronic kidney disease patients with anemia converted from Erythropoieses Stimulating Agent (ESA) treatment? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Site JP00018

Hokkaido, Japan

Site JP00004

Gunma, Japan

Site JP00005

Fukuoka, Japan

Site JP00002

Nagano, Japan

Site JP00009

Shizuoka, Japan

Site JP00020

Ishikawa, Japan

Site JP00001

Yamaguchi, Japan

Site JP00022

Kumamoto, Japan

Site JP00016

Kyoto, Japan

Site JP00010

Kumamoto, Japan

Site JP00015

Nagano, Japan

Site JP00025

Osaka, Japan

Site JP00012

Nagano, Japan

Site JP00006

Gunma, Japan

Site JP00021

Hokkaido, Japan

Site JP00023

Hyogo, Japan

Site JP00017

Aichi, Japan

Site JP00014

Tokyo, Japan

Site JP00008

Ibaraki, Japan

Site JP00007

Saitama, Japan

Site JP00024

Kumamoto, Japan

Site JP00019

Hokkaido, Japan

Site JP00013

Tottori, Japan

Site JP00011

Wakayama, Japan

Site JP00003

Niigata, Japan

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo